joining PAVmed good Matt, quarterly and for update you, call. morning, our everyone. you Thank Thank
support and thank to our like shareholders long-term your I'd proceeding, ongoing for Before commitment.
unturned to leave no long-term enhance continue stone shareholder to value. We
runway successfully most continues to advance Lucid, is through upcoming pathway that pleased commercial such milestones its fundamental has through asset, reimbursement key be advanced long-term to operations progress a its Lucid making and investors. to PAVmed's on strongest profitability. to great continue and it finance We
financed to progressing this furtherance As through drive infrastructures. we initiatives updated are we in Lucid, Veris' can well. leverage strategy PAVmed's specifically overall the and shared updated have independently strategy shareholder of subsidiaries, call, discussed strategy, which, last value The PAVmed's announced commercial Incubator PMX during like we our
Let's with starting highlights with Lucid. begin some
As we was EsoGuard noted quarter quarterly. call, revenue flat update lucid first yesterday's in quarterly
quarter-on-quarter. data First base volume supporting strengthened for the commercial EsoGuard Very XX% date secure quarter Lucid for Medicare secured engagement a to meeting grew pre-submission further payer test evidence MolDx importantly, clinical July ongoing and a was XXXX. XX, coverage.
I we am is memorandum enrolling large our mentioned, On strategy, platform. to State pilot Veris were on Cancer that Veris which Hospital with their patients on we're our the as to very focusing excited complete able Health, James I Ohio program, Care Cancer implement centers. a cancer we're new understanding a -- executing onto academic of
a clearance in we financing last And solid We -- have have pursuing and Hatch of Veris, financing.
The incubator, progress as based monitoring path last implantable which of partnership reported to FDA is in owned it's Incubator which a pending launched quarter. time, with wholly we independent we our developed Medical. on clear PMX
and PortIO, in we've so shortly. detail a separate subsidiary more for incubator, as target entity done PortIO the to for that owned about is creating first in capital talk by Our raise a wholly
just overall vision, that refer its with it with and is. think to again PAVmed's adjustments. and strategy, I But the strategy consistent we'll here what It's but summarize some
subsidiaries level. the drive and shared is Lucid PAVmed services PMX in independently financed shareholder PortIO Veris, through through at to like is strategy structure held that a are managed and value that Our holdings
infrastructure, sector actively future PMX are opportunities large technologies not-too-distant agnostic new and We're with Lucid follow based subsidiaries. Our strategy hoped a financeable is the market such to also leverage seeking subsidiaries and the that financing in the technologies PAVmed existing future. and opportunities to seek path directly Veris groundbreaking the successful are transaction we out into announce and independently on to
shared which behalf and in has medical The and shown PAVmed license here. finance. now infrastructure then services other can the as hopefully on acquire Incubator, technologies houses PMX space is of the PAVmed PortIO Diagnostics, a potentially device its infrastructure other technologies that corporate the and Veris subsidiaries: Health, and we Lucid
So webinar very yesterday just -- on I further of encourage details. brief as a from well as you to press refer couple release the Lucid. would a -- highlights on for to the
that we're has happy on opening, made As EsoGuard I mentioned with progress front. the Lucid in my the
our see and bumped that this volume $X was drive revenue slide are a can million that cycle about quarter to -- our on are about and continuing in here now reimbursement revenue force You of sales range to XX%, we strategies fixed efforts our up quarter test growth in maintain and and approximate revenue revenue our line with realization flat we management. from with through test
X highlights great that we with discussed we're events. our yesterday, progress CYC making
and operation. have a have events, we held centralized have of We now these XX telehealth
contracts pipeline of contract with entities and with contract quarters. we to those robust forward very a direct coming the executing have We engagements in looking on whom directly can various are
improve. robust that Our advocacy amounts the some And continue later, about authorization appeals, on proceeding management a we're numbers allowed so $X,XXX. will and revenue infrastructure happy process a the but cycle average variety and prior of out-of-network including physician with infrastructure Dennis continues to to improvements, talk forth.
As completing Series our we strengthened under offering. balance of preferred sheet, B just $XX million yesterday, we our mentioned
a data Institute-sponsored unprecedented data future sufficient quarter seek fact to the under believe pre-cancer the LCD. a or study group early have really publication X of from XX meeting coverage detection. the Betterment to with for of this Study in past to ] [ we -- its was technical EsoGuard really MolDx the And highlights National peer-reviewed of move secured data July important we foundational our for that results now forward, review data on a we assessment Based Cancer submission landmark from clinical shows validation positive the is EsoGuard.
across a good big and right and coverage, that's giving particularly But plans in plans. so. secure focus to a market of do is regional leverage access to area side, the activity the plans both now us On biomarker states, lot regional national legislation of with from there's board
now and on Cancer which Veris And a the Veris smartphone who which commercial-stage Veris. of through Veris PAVmed's to the company, the care. personalized story, Care is cancer which not parameters as for the sent you digital their Let's for Health, patient has are cancer health to including platform, enhance those well move through a physicians clinicians a a to platform tools, seeks as enhance physiologic for with familiar subsidiary to digital measured care app are
implantable will without data that for the provide ongoing monitor We patient also under development have physiologic need an input. that's
and is monitoring these management. of improve care tools overall through modern The mission utilize to detection longitudinal remote trends early complications, risk patient to
As our the for cancer centers, excited of for approximately looking and to our receive Hospital. we're in had They I which platform at first we've NCI-designated This the Cancer is cancer the strategy patients an infusion really cancer center. previously forward third-largest the and target the we hospital It's who updated patients. from XXX nation. comprehensive to a practices to of Veris academic is we're Comprehensive therapy, cancer in with year pilot including XX,XXX James Center have launching Cancer primary per over Veris understanding us Care University shift that large State signed memorandum centers, noted, cancer Ohio the
expect this to We imminently. launch
announcement engagement by that of look raising We're the actively triggered this forward capital and soon. consummating to
therapy like University remain typically as patients NCI-designated Large as staff. on also are concentrated State of numerous We strategic are James.. centers number and institutions arms had that with also are the numerous cancer -- engaged that infusion -- on These of other centers other areas. James. the focus metropolitan centers many We these comprehensive have those venture Ohio large those
access our cardiac time -- part port, of also and is progress the of we key made Veris implantable on long-term the data platform. at to an Bluetooth with that's the to implanted intended which mention provides continuous of have through connectivity relaying the And to this. excellent vision monitoring additional To monitor be is vascular
development path submission process proceed have to We once and clearance and financing. secure FDA will towards we we a launch, clear with independent commercial and that FDA
monitor billing XXX% the it the implantable for because the with assures platform compliance RPM of important The long-term is requirements. value patient
advance PMX last them created in is And them take with at products individual incubator partnership our Hatch we was pause commercialization. is for put subsidiaries colleagues into individual PMX discuss that quarter. them that Finally, Medical. and the previously an and had announced to let's we bring on which to to XXXX the raise Incubator, capital idea here in individual
to of PortIO is and Corp., a as raising a target that actively now subsidiary the advance incubator, first we've entity this project. separate corporate is Our PortIO capital established
vascular ports feature means inserted those and marrow for know Access with and other key me the no vascular Vascular typical is with PortIO intraosseous, deeper and first bottom get. requirements use, is for it's for bone or that implantable that patients would let the of designed Those of analogous access marrow, bone long-term don't. introduction a while who've been give long-term bone into PAVmed the you implantable you that's which it's direct to PortIO, is marrow provides you but who access is costly long-term long-term you the as therefore, it it as access do see to there, can device has maintenance-free, on right ports, into port. flushing The the chemotherapy labor-intensive because every the a
venous have clinical access. will patients population, preserved unmet it this those reduced access. and infection for reduced including have who in traditional And have their whom expect to failure particularly addresses a large relative in veins poor veins need those future be large to dialysis renal need rates a We diverse target very complications, who
the these the upwards addressable billion. We is total $X target expect spectrum the across that population market of -- of
we results implantable have excellent the on Colombia, had function first-in-human of no South robust prior port. to our with had project protection. the America completed that putting excellent And pause, in study complications IP We and
IDE the We've we clear the long engagement completion path them an study. de the have upon so. submission pathway secured a a once protocol financing have novo begin We following with study to of to of FDA through had would FDA. do final That to a
at for give we under this update. and XX%, be codes With a access existing least us The I'll target that, the devices. financial insertion on Dennis expect to for margins reimbursed to vascular it to baton technology of pass is
